CytomX Therapeutics, Inc.
NASDAQ:CTMXBiotechnology
-$0.03 today
- Market cap
- $409.85M
- Beta
- 2.09
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.33
Volume 4.39M
Average 4.99M
CTMX Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
CytomX Therapeutics, Inc.NASDAQ: CTMX
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin narrows to -191.8%
Operating margin was -191.8% in Q1 FY2026, down 236.2 pp from a year earlier. On a trailing-twelve-month basis it was -181.9%, down 206.3 pp year over year. Over 3 fiscal years it widened by 161.3 pp.
Context
- Operating margin widened in 2 of the last 3 fiscal years.
What to watch
Whether operating margin reaches the consensus estimate from 5 analysts of -245.1% for the fiscal year ending Dec 2026, down from -29.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -191.8%+4021.2 pp QoQ
- Last fiscal yearDec 2025
- -29.3%-47.4 pp YoY
- LTMMar 2026
- -181.9%-206.3 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -29.3%
- Year-over-year change
- -47.4pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -29.3% | -47.4pp |
| FY2024 | 2024-12-31 | 18.1% | +24.5pp |
| FY2023 | 2023-12-31 | -6.4% | +184.2pp |
| FY2022 | 2022-12-31 | -190.6% | +120.4pp |
| FY2021 | 2021-12-31 | -311.0% | — |
Operating Margin vs competitors
How CTMX compares with its peers on the latest reported figures
- CTMX's LTM Mar 2026 operating margin of -181.9% is the 6th highest of the 10 companies compared; the peer median is -149.6%.
- Its year-over-year change of -206.3 pp is the 7th highest of 8, against a peer median of +24.7 pp.
- Over three fiscal years its change of +161.3 pp compares with a peer median of -21.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Aug 2026 | 41.3% | +360.6 pp | +135.8 pp | |
| LTM Sep 2026 | 16.6% | +69.1 pp | -119.0 pp | |
| LTM Mar 2026 | -40.5% | +24.7 pp | +32.2 pp | |
| LTM Mar 2026 | -115.5% | +261.4 pp | +87.9 pp | |
| LTM Mar 2026 | -149.6% | +15.9 pp | -74.5 pp | |
| LTM Mar 2026 | -181.9% | -206.3 pp | +161.3 pp | |
| LTM Jun 2026 | -205.8% | -128.2 pp | -91.2 pp | |
| LTM Mar 2026 | -619.6% | — | — | |
| LTM Jun 2024 | -4534.8% | — | +623.6 pp | |
| LTM Sep 2026 | -298657.1% | -288801.8 pp | -14271.0 pp | |
VRXAVeraxa Biotech Holding AG | — | — | — | — |
| Peer median (excluding CTMX) | -149.6% | +24.7 pp | -21.1 pp | |
Competitors are the stored peer set for CTMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 37.31M | 53.16M | 101.21M | 138.1M | 76.2M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 37.31M | 53.16M | 101.21M | 138.1M | 76.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 114.19M | 111.65M | 77.68M | 83.38M | 68.73M |
| Selling, General & Admin | 39.16M | 42.85M | 30.02M | 29.73M | 29.84M |
| Operating Expenses | 153.35M | 154.5M | 107.7M | 113.11M | 98.57M |
| Depreciation & Amortization | 2.71M | 2.44M | 2.18M | 1.77M | 1.38M |
| EBITDA | (113.16M) | (96.87M) | 5.5M | 33.86M | (15.75M) |
| EBITDA Margin | -303.3% | -182.2% | 5.4% | 24.5% | -20.7% |
| Operating Income | (116.04M) | (101.34M) | (6.48M) | 25M | (22.36M) |
| Operating Margin | -311.0% | -190.6% | -6.4% | 18.1% | -29.3% |
| Interest Income | 255K | 1.68M | 9.84M | 7.14M | 5.21M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 172K | 2.02M | 9.81M | 7.1M | 5.23M |
| Income Before Tax | (115.87M) | (99.32M) | 3.32M | 32.09M | (17.13M) |
| Pre-Tax Margin | -310.5% | -186.8% | 3.3% | 23.2% | -22.5% |
| Income Tax Expense | 0 | 0 | 3.89M | 224K | 238K |
| Net Income | (115.87M) | (99.32M) | (569K) | 31.87M | (17.37M) |
| Net Margin | -310.5% | -186.8% | -0.6% | 23.1% | -22.8% |
| EPS (Basic) | (1.26) | (1.48) | (0.01) | 0.38 | (0.15) |
| EPS (Diluted) | (1.26) | (1.48) | (0.01) | 0.38 | (0.15) |
| Weighted Avg Shares | 64.15M | 65.74M | 73.81M | 84.44M | 137.94M |
| Weighted Avg Shares (Diluted) | 64.15M | 65.74M | 73.81M | 84.75M | 137.94M |
CytomX Therapeutics, Inc.
NASDAQ:CTMX
Intrinsic Alpha fair value
Locked
Current Price
$1.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.